Literature DB >> 12518248

In vitro and in vivo angiogenesis in PC12 pheochromocytoma cells is mediated by vascular endothelial growth factor.

M Middeke1, S Hoffmann, I Hassan, A Wunderlich, L C Hofbauer, A Zielke.   

Abstract

Angiogenesis, the formation of new blood vessels from existing vascular endothelium, is essential for tumor growth. Vascular endothelial growth factor (VEGF) is an endotheliumspecific mitogen and regulator of angiogenesis. Angiogenesis has been associated to the malignant phenotype of pheochromocytomas and is readily observed in experimental pheochromocytomas. Although VEGF gene expression has already been demonstrated in the rat PC12 cell line, the detailed mechanisms of action are not known. We have, therefore, studied angiogenesis in the rat PC12 pheochromocytoma cell line in vitro and in vivo. VEGF gene expression and accumulation of VEGF protein in cytoplasm and conditioned medium of PC12 cells was found. Conditioned medium from PC12 cells significantly increased proliferation of VEGF-dependent endothelial cells from human umbilical veins, and this effect reversed upon addition of a neutralizing anti-VEGF antibody. Dexamethasone and nerve growth factor (NGF) increased VEGF mRNA expression and accumulation of VEGF protein of PC12 subclones with established metastatic activity in vivo. PC12 cells xenotransplanted to nude mice had marked VEGF expression and induced host angiogenesis, confirmed by the presence of CD34-positive endothelial cells in the experimental PC12 tumors. When NGF-primed PC12 cells were immobilized in Matrigel supplemented with rising concentrations of the growth factor and xenotransplanted, increasing NGF resulted in tumors with smaller areas of necrosis and increased vital tumor volume. These results suggest that VEGF is a mediator of angiogenesis in the PC12 pheochromocytoma cell line, and that dexamethasone and NGF affect VEGF expression. Our data further suggest that NGF may contribute to angiogenesis in experimental pheochromocytoma.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12518248     DOI: 10.1055/s-2002-36424

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  12 in total

1.  Functional thyrotropin receptor attenuates malignant phenotype of follicular thyroid cancer cells.

Authors:  S Hoffmann; K Maschuw; I Hassan; A Wunderlich; S Lingelbach; A Ramaswamy; L C Hofbauer; A Zielke
Journal:  Endocrine       Date:  2006-08       Impact factor: 3.633

2.  Catecholamine-Synthesizing Enzymes in Pheochromocytoma and Extraadrenal Paraganglioma.

Authors:  Sachiko Konosu-Fukaya; Kei Omata; Yuta Tezuka; Yoshikiyo Ono; Yayoi Aoyama; Fumitoshi Satoh; Fumiyoshi Fujishima; Hironobu Sasano; Yasuhiro Nakamura
Journal:  Endocr Pathol       Date:  2018-12       Impact factor: 3.943

3.  NGF activation of TrkA induces vascular endothelial growth factor expression via induction of hypoxia-inducible factor-1α.

Authors:  Katsuya Nakamura; Fei Tan; Zhijie Li; Carol J Thiele
Journal:  Mol Cell Neurosci       Date:  2010-12-09       Impact factor: 4.314

Review 4.  Current and future therapeutic approaches for metastatic pheochromocytoma and paraganglioma: focus on SDHB tumors.

Authors:  J Matro; A Giubellino; K Pacak
Journal:  Horm Metab Res       Date:  2013-01-15       Impact factor: 2.936

5.  Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines.

Authors:  S Hoffmann; A Burchert; A Wunderlich; Y Wang; S Lingelbach; L C Hofbauer; M Rothmund; A Zielke
Journal:  Endocrine       Date:  2007-04       Impact factor: 3.633

6.  Color-coded duplex endoscopic ultrasound of the adrenals.

Authors:  S Meyer; M-A von Mach; D Ivan; S Schäfer; N Habbe; B Kann; P H Kann
Journal:  J Endocrinol Invest       Date:  2008-10       Impact factor: 4.256

7.  Nerve growth factor induces vascular endothelial growth factor expression in granulosa cells via a trkA receptor/mitogen-activated protein kinase-extracellularly regulated kinase 2-dependent pathway.

Authors:  Marcela Julio-Pieper; Patricia Lozada; Veronica Tapia; Margarita Vega; Cristián Miranda; David Vantman; Sergio R Ojeda; Carmen Romero
Journal:  J Clin Endocrinol Metab       Date:  2009-05-19       Impact factor: 5.958

8.  Targeting the EGF/VEGF-R system by tyrosine-kinase inhibitors--a novel antiproliferative/antiangiogenic strategy in thyroid cancer.

Authors:  S Hoffmann; S Gläser; A Wunderlich; S Lingelbach; C Dietrich; A Burchert; H Müller; M Rothmund; A Zielke
Journal:  Langenbecks Arch Surg       Date:  2006-10-12       Impact factor: 3.445

9.  Differential expression of the angiogenesis growth factors in psoriasis vulgaris.

Authors:  Siaw-Cheok Liew; Esha Das-Gupta; Srikumar Chakravarthi; Shew-Fung Wong; Nagarajah Lee; Najeeb Safdar; Adawiyah Jamil
Journal:  BMC Res Notes       Date:  2012-07-03

10.  Immunohistochemical markers of the hypoxic response can identify malignancy in phaeochromocytomas and paragangliomas and optimize the detection of tumours with VHL germline mutations.

Authors:  D J Pinato; R Ramachandran; S T K Toussi; M Vergine; N Ngo; R Sharma; T Lloyd; K Meeran; F Palazzo; N Martin; B Khoo; R Dina; T M Tan
Journal:  Br J Cancer       Date:  2012-12-20       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.